CanSino Biologics (HKSE:06185) Days Sales Outstanding : 314.22 (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Days Sales Outstanding?

CanSino Biologics's average Accounts Receivable for the three months ended in Jun. 2024 was HK$634.4 Mil. CanSino Biologics's Revenue for the three months ended in Jun. 2024 was HK$184.2 Mil. Hence, CanSino Biologics's Days Sales Outstanding for the three months ended in Jun. 2024 was 314.22.

The historical rank and industry rank for CanSino Biologics's Days Sales Outstanding or its related term are showing as below:

HKSE:06185' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.59 Med: 304 Max: 798.51
Current: 400.94

During the past 8 years, CanSino Biologics's highest Days Sales Outstanding was 798.51. The lowest was 7.59. And the median was 304.00.

HKSE:06185's Days Sales Outstanding is ranked worse than
97.83% of 968 companies
in the Drug Manufacturers industry
Industry Median: 71.165 vs HKSE:06185: 400.94

CanSino Biologics's Days Sales Outstanding increased from Jun. 2023 (0.00) to Jun. 2024 (314.22).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

CanSino Biologics Days Sales Outstanding Historical Data

The historical data trend for CanSino Biologics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Days Sales Outstanding Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

425.92

7.59

182.08

798.51

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Days Sales Outstanding	Get a 7-Day Free Trial														-	456.12	343.71	493.61	314.22

Competitive Comparison of CanSino Biologics's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CanSino Biologics's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's Days Sales Outstanding falls into.

CanSino Biologics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

CanSino Biologics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (955.338	+	696.608)	/	2 )	/	377.553	*	365
=	825.973					/	377.553	*	365
=	798.51

CanSino Biologics's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding (Q: Jun. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2024 )	+	Accounts Receivable (A: Jun. 2024 ))	/	count )	/	Revenue (A: Jun. 2024 )	*	Days in Period
=	( (646.491	+	622.368)	/	2 )	/	184.237	*	365 / 4
=	634.4295					/	184.237	*	365 / 4
=	314.22

CanSino Biologics (HKSE:06185) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

CanSino Biologics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Days Sales Outstanding

Traded in Other Exchanges

CASBF:USA CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.

Executives

Yu Xuefeng	2501 Other
Chao Shou Bai	2202 Interest of your spouse
Mao Helen Huihua	2201 Interest of corporation controlled by you
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2201 Interest of corporation controlled by you
Qm29 Limited	2101 Beneficial owner
Qiu Dongxu	2501 Other
Zhu Tao
Orbimed Capital Llc	2102 Investment manager

CanSino Biologics Headlines

No Headlines